Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial

被引：6

作者：

Poveda Velasco, A. M. ^{[1
]}

Lheureux, S. ^{[2
]}

Colombo, N. ^{[3
]}

Cibula, D. ^{[4
]}

Elstrand, M. ^{[5
]}

Weberpals, J. ^{[6
]}

Bjurberg, M. ^{[7
]}

Oaknin, A. ^{[8
]}

Sikorska, M. ^{[9
]}

Gonzalez Martin, A. J. ^{[10
]}

Madry, R. ^{[11
,12
]}

Rubio Perez, M. J. ^{[13
]}

Ledermann, J. A. ^{[14
,15
]}

Ozgoren, O. ^{[16
]}

Barnicle, A. ^{[17
]}

Marshall, H. ^{[18
]}

Bashir, Z. ^{[16
]}

Skof, E. ^{[19
]}

机构：

[1] Initia Oncol, Med Oncol Dept, Valencia, Spain

[2] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON, Canada

[3] Univ Milano Bicocca, European Inst Oncol IRCCS, Gynecol Oncol Dept, Milan, Italy

[4] Charles Univ Prague, Gen Univ Hosp Prague, Fac Med 1, Dept Obstet & Gynaecol, Prague, Czech Republic

[5] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Gynaecol Oncol, Oslo, Norway

[6] Ottawa Hosp Res Inst, Dept Obstet & Gynaecol, Ottawa, ON, Canada

[7] Lund Univ, Skane Univ Hosp, Dept Oncol, Lund, Sweden

[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[9] Olsztyn Prov Specialist Hosp, Oncol Gynaecol Ward, Olsztyn, Poland

[10] Clin Univ Navarra, Med Oncol Dept, Madrid, Spain

[11] Poznan Univ Med Sci, Dept Oncol Gynaecol, Poznan, Poland

[12] PGOG, Poznan, Poland

[13] Hosp Univ Reina Sofia, Oncol, Cordoba, Spain

[14] UCL, UCL Canc Inst, London, England

[15] UCL Hosp, London, England

[16] AstraZeneca, Global Med Affairs, Cambridge, England

[17] AstraZeneca, Translat Med, Oncol R&D, Cambridge, England

[18] AstraZeneca, GMA Payer Biometr, Oncol R&D, Cambridge, England

[19] Inst Oncol Ljubljana, Dept Med Oncol, Ljubljana, Slovenia

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.659

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

531P

引用

页码：S790 / S790

页数：1

共 50 条

[1] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Poveda, A.
Lheureux, S.
Colombo, N.
Cibula, D.
Lindemann, K.
Weberpals, J.
Bjurberg, M.
Oaknin, A.
Sikorska, M.
Gonzalez-Martin, A.
Madry, R.
Perez, M. J. Rubio
Ledermann, J.
Davidson, R.
Blakeley, C.
Bennett, J.
Barnicle, A.
Skof, E.
GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
[2] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
Poveda, Andres
Lheureux, Stephanie
Colombo, Nicoletta
Cibula, David
Lindemann, Kristina
Weberpals, Johanne, I
Bjurberg, Maria
Oaknin, Ana
Sikorska, Magdalena
Gonzalez Martin, Antonio
Madry, Radoslaw
Rubio Perez, Maria Jesus
Davidson, Richard
Blakeley, Christopher
Bennett, James
Barnicle, Alan
Skof, Erik
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.
Poveda, Andres
Lheureux, Stephanie
Colombo, Nicoletta
Cibula, David
Lindemann, Kristina
Weberpals, Johanne I.
Bjurberg, Maria
Oaknin, Ana
Sikorska, Magdalena
Gonzalez Martin, Antonio
Madry, Radoslaw
Jesus Rubio, Maria
Ledermann, Jonathan A.
Davidson, Richard
Blakeley, Christopher
Bennett, James
Brown, Jessica
Skof, Erik
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
Lindemann, K.
Skof, E.
Colombo, N.
Gonzalez-Martin, A.
Davidson, R.
Blakeley, C.
Bennett, J.
Barnicle, A.
Poveda, A.
ANNALS OF ONCOLOGY, 2021, 32 : S738 - S739
[5] Maintenance olaparib monotherapy for platinum-sensitive relapsed ovarian cancer in patients without a germline BRCA1/BRCA2 mutation: Secondary safety results from the phase IIIb OPINION study
Colombo, Nicoletta
Madry, Radoslaw
Skof, Erik
Weberpals, Johanne
Blakeley, Chris
Marshall, Helen
Brickel, Neil
Poveda, Andres
GYNECOLOGIC ONCOLOGY, 2022, 166 : S81 - S82
[6] OPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)
Poveda, A. M.
Davidson, R.
Blakeley, C.
Milner, A.
ANNALS OF ONCOLOGY, 2018, 29
[7] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
Penson, R. T.
Valencia, R. V.
Cibula, D.
Colombo, N.
Ill, C. L.
Bidzinski, M.
Kim, J. W.
Nam, J. H.
Madry, R.
Hernandez, C. H.
Mora, P.
Ryu, S. Y.
Milenkova, T.
Lowe, E.
Barker, L.
Scambia, G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
[8] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
Penson, Richard T.
Valencia, Ricardo Villalobos
Cibula, David
Colombo, Nicoletta
Leath, Charles A.
Bidzinski, Mariusz
Kim, Jae-Weon
Nam, Joo-Hyun
Madry, Radoslaw
Hernandez, Carlos Hernandez
Mora, Paulo Alexandre Ribeiro
Ryu, Sang Young
Milenkova, Tsveta
Lowe, Elizabeth S.
Barker, Laura
Scambia, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design
Poveda, Andres M.
Davidson, Richard
Blakeley, Christopher
Milner, Alvin
FUTURE ONCOLOGY, 2019, 15 (32) : 3651 - 3663
[10] SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).
Lowe, Elizabeth S.
Jayawardene, Deepthi
Penson, Richard T.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →